NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, has presented results from ESTABLISH1, an observational study of neuromuscular function in patients with the inherited neurological conditions…
Source: www.labiotech.eu – Read more
StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data
The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in patients treated with its gene
